Merck & Co., Inc. reported a 4% increase in sales to $17.3 billion in Q3 2025, highlighting significant growth in key products while completing the acquisition of Verona Pharma to enhance its treatment portfolio.

Target Information

Merck & Co., Inc., based in Rahway, New Jersey, is a global leader in pharmaceuticals and has been dedicated to improving health outcomes for over 130 years. The company specializes in the development of innovative medicines and vaccines aimed at treating various diseases in both humans and animals. Their product offerings include breakthrough therapies in oncology, vaccines for infectious diseases, and treatments for chronic conditions, exemplifying their commitment to research and development, as well as their substantial investment in new drug pipelines.

In the third quarter of 2025, Merck reported total worldwide sales of $17.3 billion, marking a 4% increase over the previous year. Noteworthy sales included KEYTRUDA, a cornerstone of their oncology portfolio, which generated $8.1 billion in sales—a growth of 10%. Other products showed varying performance, with significant declines in sales seen in GARDASIL/GARDASIL 9, while new products such as WINREVAIR (sales of $360 million) experienced robust growth.

Industry Overview

Merck operates within the pharmaceutical industry, which is currently marked by heightened competition and rapid advancements in scientific research. The United States remains the world's largest pharmaceutical market, characterized by significant investment in R&D alongside stringent regula